Design of targeted B cell killing agents

Area of Science:

• Immunology
• Biotechnology
• Therapeutics

Background:

• B cells are key players in autoimmune diseases, producing autoantibodies and pro-inflammatory cytokines.
• Current B cell depletion therapies like Rituximab have systemic side effects.
• Improved targeted therapies are needed to selectively eliminate autoreactive B cells.

Purpose of the Study:

• To design and evaluate novel, genetically engineered B cell killers for targeted autoimmune disease therapy.
• To assess the efficacy and specificity of various immunotoxins (ITs) against B cells.
• To identify IT candidates with an optimal balance of targeting, cytotoxicity, and specificity.

Main Methods:

• Constructed immunotoxins by fusing targeting sequences (c-myc epitope) with cytotoxic agents (barnase, Pseudomonas toxin, Shiga-like toxin, Fc domain).
• Utilized a c-MYC hybridoma cell line as a model for targeted B cell depletion.
• Evaluated ITs in vitro for functional activity and ex vivo for specificity using c-MYC and irrelevant hybridoma cell lines.
• Assessed the impact of ITs on B cell depletion and autoantibody production in native splenocyte cultures.

Main Results:

• Pseudomonas-containing IT showed high cytotoxicity but lacked specificity.
• Shiga-like toxin IT exhibited moderate cytotoxicity and specificity.
• Barnase and Fc-containing ITs demonstrated an excellent balance of efficacy and specificity.
• Barnase and Fc ITs selectively depleted c-myc-specific B cells and reduced anti-c-myc antibody production.

Conclusions:

• Genetically engineered immunotoxins offer a promising strategy for targeted B cell depletion in autoimmune diseases.
• Barnase and Fc-based immunotoxins present a favorable therapeutic profile due to their selective action and balanced properties.
• These novel B cell killers hold significant potential for improving autoimmune disease treatment by minimizing off-target effects.